Cargando…

Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS target. Tofacitinib is an FDA-approved immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Figueroa-Romero, Claudia, Monteagudo, Alina, Murdock, Benjamin J., Famie, Joshua P., Webber-Davis, Ian F., Piecuch, Caroline E., Teener, Samuel J., Pacut, Crystal, Goutman, Stephen A., Feldman, Eva L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859451/
https://www.ncbi.nlm.nih.gov/pubmed/35197969
http://dx.doi.org/10.3389/fimmu.2022.773288
_version_ 1784654465147600896
author Figueroa-Romero, Claudia
Monteagudo, Alina
Murdock, Benjamin J.
Famie, Joshua P.
Webber-Davis, Ian F.
Piecuch, Caroline E.
Teener, Samuel J.
Pacut, Crystal
Goutman, Stephen A.
Feldman, Eva L.
author_facet Figueroa-Romero, Claudia
Monteagudo, Alina
Murdock, Benjamin J.
Famie, Joshua P.
Webber-Davis, Ian F.
Piecuch, Caroline E.
Teener, Samuel J.
Pacut, Crystal
Goutman, Stephen A.
Feldman, Eva L.
author_sort Figueroa-Romero, Claudia
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS target. Tofacitinib is an FDA-approved immunomodulating small molecule which suppresses immune cell function by blocking proinflammatory cytokine signaling. This includes the cytokine IL-15 which is the primary cytokine associated with NK cell function and proliferation. However, the impact of tofacitinib on NK activation and cytotoxicity has not been thoroughly investigated, particularly in ALS. We therefore tested the ability of tofacitinib to suppress cytotoxicity and cytokine production in an NK cell line and in primary NK cells derived from control and ALS participants. We also investigated whether tofacitinib protected ALS neurons from NK cell cytotoxicity. Finally, we conducted a comprehensive pharmacokinetic study of tofacitinib in mice and tested the feasibility of administration formulated in chow. Success was assessed through the impact of tofacitinib on peripheral NK cell levels in mice. We found tofacitinib suppressed IL-15-induced activation as measured by STAT1 phosphorylation, cytotoxicity, pro-inflammatory gene expression, and pro-inflammatory cytokine secretion in both an NK cell line and primary NK cells. Furthermore, tofacitinib protected ALS neurons from NK cell-mediated cytotoxicity. In mice, we found tofacitinib bioavailability was 37% in both male and female mice; using these data we formulated mouse containing low and high doses of tofacitinib and found that the drug suppressed peripheral NK cell levels in a dose-dependent manner. These results demonstrate that tofacitinib can suppress NK cell function and may be a viable therapeutic strategy for ALS.
format Online
Article
Text
id pubmed-8859451
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88594512022-02-22 Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis Figueroa-Romero, Claudia Monteagudo, Alina Murdock, Benjamin J. Famie, Joshua P. Webber-Davis, Ian F. Piecuch, Caroline E. Teener, Samuel J. Pacut, Crystal Goutman, Stephen A. Feldman, Eva L. Front Immunol Immunology Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS target. Tofacitinib is an FDA-approved immunomodulating small molecule which suppresses immune cell function by blocking proinflammatory cytokine signaling. This includes the cytokine IL-15 which is the primary cytokine associated with NK cell function and proliferation. However, the impact of tofacitinib on NK activation and cytotoxicity has not been thoroughly investigated, particularly in ALS. We therefore tested the ability of tofacitinib to suppress cytotoxicity and cytokine production in an NK cell line and in primary NK cells derived from control and ALS participants. We also investigated whether tofacitinib protected ALS neurons from NK cell cytotoxicity. Finally, we conducted a comprehensive pharmacokinetic study of tofacitinib in mice and tested the feasibility of administration formulated in chow. Success was assessed through the impact of tofacitinib on peripheral NK cell levels in mice. We found tofacitinib suppressed IL-15-induced activation as measured by STAT1 phosphorylation, cytotoxicity, pro-inflammatory gene expression, and pro-inflammatory cytokine secretion in both an NK cell line and primary NK cells. Furthermore, tofacitinib protected ALS neurons from NK cell-mediated cytotoxicity. In mice, we found tofacitinib bioavailability was 37% in both male and female mice; using these data we formulated mouse containing low and high doses of tofacitinib and found that the drug suppressed peripheral NK cell levels in a dose-dependent manner. These results demonstrate that tofacitinib can suppress NK cell function and may be a viable therapeutic strategy for ALS. Frontiers Media S.A. 2022-02-07 /pmc/articles/PMC8859451/ /pubmed/35197969 http://dx.doi.org/10.3389/fimmu.2022.773288 Text en Copyright © 2022 Figueroa-Romero, Monteagudo, Murdock, Famie, Webber-Davis, Piecuch, Teener, Pacut, Goutman and Feldman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Figueroa-Romero, Claudia
Monteagudo, Alina
Murdock, Benjamin J.
Famie, Joshua P.
Webber-Davis, Ian F.
Piecuch, Caroline E.
Teener, Samuel J.
Pacut, Crystal
Goutman, Stephen A.
Feldman, Eva L.
Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis
title Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis
title_full Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis
title_fullStr Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis
title_full_unstemmed Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis
title_short Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis
title_sort tofacitinib suppresses natural killer cells in vitro and in vivo: implications for amyotrophic lateral sclerosis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859451/
https://www.ncbi.nlm.nih.gov/pubmed/35197969
http://dx.doi.org/10.3389/fimmu.2022.773288
work_keys_str_mv AT figueroaromeroclaudia tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT monteagudoalina tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT murdockbenjaminj tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT famiejoshuap tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT webberdavisianf tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT piecuchcarolinee tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT teenersamuelj tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT pacutcrystal tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT goutmanstephena tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis
AT feldmaneval tofacitinibsuppressesnaturalkillercellsinvitroandinvivoimplicationsforamyotrophiclateralsclerosis